Table 5

Age-adjusted prevalence and trend in HbA1c treatment target achievement among women and men with self-reported diabetes aged 40–84: the Tromsø Study 1994–2016

Tromsø 4Tromsø 5Tromsø 6Tromsø 7OR (95% CI)*P value
Target achievement, % (n)
WomenN=97N=150N=288N=496
Guideline target†70.1 (63)67.3 (93)79.2 (222)56.7 (282)0.67 (0.55 to 0.81)<0.001
 Without medication†74.0 (17)77.5 (37)89.3 (75)83.6 (130)1.26 (0.81 to 1.96)0.297
 With medication†63.9 (35)56.3 (53)73.1 (144)43.8 (146)0.59 (0.47 to 0.75)<0.001
HbA1c ≤7.0%57.3 (49)52.4 (66)60.4 (170)56.1 (282)0.99 (0.83 to 1.18)0.921
HbA1c <7.5%62.6 (54)61.6 (83)73.9 (209)66.9 (337)1.07 (0.89 to 1.29)0.460
MenN=95N=122N=318N=572
Guideline target†62.0 (56)58.6 (70)62.2 (191)46.9 (269)0.69 (0.57 to 0.82)<0.001
 Without medication†71.9 (16)65.7 (13)84.9 (40)76.1 (94)1.11 (0.72 to 1.71)0.634
 With medication†55.1 (34)58.0 (55)57.7 (149)38.5 (171)0.61 (0.49 to 0.75)<0.001
HbA1c ≤7.0%50.8 (43)40.1 (44)46.2 (141)46.4 (269)0.99 (0.84 to 1.18)0.943
HbA1c <7.5%58.4 (51)57.8 (66)58.1 (180)60.6 (350)1.07 (0.90 to 1.27)0.461
  • Proportions, OR with CIs and p value for trend are adjusted for age across surveys using generalised estimating equation models. N represents crude numbers.

  • Sample sizes are varying due to missing data on medication use.

  • *ORs for proportions are presented per 10 years.

  • †HbA1c treatment targets according to Norwegian diabetes guidelines at the time of each survey: Tromsø 4: HbA1c <7.5% (>70 years: HbA1c <8.5%); Tromsø 5 and Tromsø 6: HbA1c <7.5% (>75 years: HbA1c <9.0%); Tromsø 7: HbA1c ≤7.0%.

  • HbA1c, glycated haemoglobin.